A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial

BACKGROUND: Pheochromocytoma (PCC) and paraganglioma (PGL) are uncommon neoplasms with high morbidity in advanced stages. Effective systemic treatments are limited. METHODS: A multisite phase 2 trial evaluated sunitinib in patients with progressive PCC/PGL. Patients received 50 mg orally for 4–6 wee...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Kane, Grainne M, Ezzat, Shereen, Joshua, Anthony M., Bourdeau, Isabelle, Leibowitz-Amit, Raya, Olney, Harold J., Krzyzanowska, Monika, Reuther, Dean, Chin, Soo, Wang, Lisa, Brooks, Kelly, Hansen, Aaron R., Asa, Sylvia L., Knox, Jennifer J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738062/
https://www.ncbi.nlm.nih.gov/pubmed/31105270
http://dx.doi.org/10.1038/s41416-019-0474-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738062/
https://www.ncbi.nlm.nih.gov/pubmed/31105270
http://dx.doi.org/10.1038/s41416-019-0474-x

Ejemplares similares